CN109232995A - The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof - Google Patents
The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109232995A CN109232995A CN201810895373.8A CN201810895373A CN109232995A CN 109232995 A CN109232995 A CN 109232995A CN 201810895373 A CN201810895373 A CN 201810895373A CN 109232995 A CN109232995 A CN 109232995A
- Authority
- CN
- China
- Prior art keywords
- temperature
- cell material
- adjustable response
- sensitive hydrogel
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 44
- 239000000463 material Substances 0.000 title claims abstract description 31
- 230000004044 response Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000499 gel Substances 0.000 claims abstract description 31
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000811 xylitol Substances 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 28
- 229960002675 xylitol Drugs 0.000 claims abstract description 28
- 235000010447 xylitol Nutrition 0.000 claims abstract description 28
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 17
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 17
- 230000007704 transition Effects 0.000 claims abstract description 17
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 15
- 239000001923 methylcellulose Substances 0.000 claims abstract description 15
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 230000009514 concussion Effects 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 abstract description 11
- 239000011734 sodium Substances 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010850 salt effect Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/08—Cellulose derivatives
- C08J2301/26—Cellulose ethers
- C08J2301/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2471/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
- C08K2003/321—Phosphates
- C08K2003/324—Alkali metal phosphate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/16—Halogen-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates
- C08K5/053—Polyhydroxylic alcohols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
- C08K5/098—Metal salts of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于智能材料，高分子材料和生物医学工程领域，具体涉及一种可以调节响应温度的温敏性水凝胶包载细胞材料及其制备方法与应用。载细胞温敏性水凝胶，包括以下重量百分数的原料组分：甲基纤维素，12wt％；PEG‑20000，7.4wt％；无毒无机钠盐，1.4wt％；木糖醇，0～16wt％；余量为水。所述无毒无机钠盐为Na2HPO3.12H2O本发明的一种可以调节响应温度的温敏性水凝胶包载细胞材料，可以通过调节木糖醇含量调节起温敏响应温度并且无生物毒性。在低温时，保持透明液态，当升温至相转变温度时，能转变为凝胶态。并且材料无生物毒性，可以包载保护细胞，注射到体内。
The invention belongs to the fields of intelligent materials, polymer materials and biomedical engineering, and in particular relates to a temperature-sensitive hydrogel-encapsulated cell material that can adjust the response temperature and a preparation method and application thereof. Cell-loaded thermosensitive hydrogel, comprising the following raw material components by weight: methyl cellulose, 12wt%; PEG-20000, 7.4wt%; non-toxic inorganic sodium salt, 1.4wt%; xylitol, 0- 16 wt%; the balance is water. The non-toxic inorganic sodium salt is Na 2 HPO 3 .12H 2 O. The temperature-sensitive hydrogel-encapsulated cell material of the present invention that can adjust the response temperature can adjust the temperature-sensitive response temperature by adjusting the content of xylitol. And no biological toxicity. At low temperature, it maintains a transparent liquid state, and when heated to the phase transition temperature, it can be transformed into a gel state. And the material has no biological toxicity, and can encapsulate protective cells and inject into the body.
Description
Technical field
The invention belongs to intellectual material, high molecular material and biomedical engineering field, and in particular to a kind of adjustable
The temperature-sensitive hydrogel of response temperature contains cell material and the preparation method and application thereof.
Background technique
Stem cell therapy has entered clinical test as a kind of promising method of tissue repair, a plurality of types of stem cells
Stage.But direct injection transplanting allogeneic or when heterogenous cell, they the effect of be detained by transplanted cells and implantation amount
Lower limit, the retention rate of cell is very low, and there are inflammation and the potential risks of immune response.Therefore hydrogel is as one
For a cell carrier package cell when being injected into internal, protecting it from being damaged is to have very much important (van Berlo, J.H.；
Molkentin,J.D.An Emerging Consensus on Cardiac Regeneration.Nat.Med.2014,20,
1386-93)。
A kind of attractive strategy is the water-setting that stem cell (such as CSCs) is wrapped in hydrogel, and cell is loaded into
Glue is delivered in injury tissue.Temperature-sensitive hydrogel is due to being easy to administration and minimally-invasive treatment, note with good biocompatibility
It penetrates and polyalcohol hydrogel is used to be widely studied the promising carrier as the lasting various drugs of conveying.Particularly, injectable
Thermosensitive aquagel presents to flow freely to be dissolved under room temperature or low temperature, but as the temperature rises, becomes semisolid mechanical water
Gel.Therefore, frangible therapeutic agent (such as protein, polypeptide, cell or other small molecules) may be easy to fall at low temperature
Then collosol state is carried cell aggregation object solution and spontaneously forms water in situ under body temperature after being injected in vivo using conventional syringe
Gel.Cell is effectively delivered to target site, and not by beneficial cellular uptake and bioavilability and milder
Good reaction improves therapeutic immunization response.In particular, thermosensitive aquagel can be injected into target site by Noninvasive management.
There are manufacturing cost height, complex procedures to have notably and there is a small amount of bio-toxicity for current cell carrier.
Summary of the invention
The object of the present invention is to provide a kind of temperature-sensitive hydrogel of adjustable response temperature contain cell material and
Preparation method and application.Hydrogel provided by the invention is liquid at room temperature, is solidifying when being higher than its phase transition temperature
Colloidal state, and the phase transition temperature of gel can be adjusted by the content of xylitol according to diseased region situation；Preparation method letter
It is single cheap nontoxic, it is suitble to industrialization, avoids the side effect of organic solvent, accomplished the safeguard protection to cell.
In order to achieve the above objectives, the present invention provides the following technical scheme that
It is a kind of it is adjustable response temperature temperature-sensitive hydrogel contain cell material, the group including following weight percent
Point:
Methylcellulose, 12wt%；
PEG-20000,7.4wt%；
Non-toxic inorganic sodium salt, 1.4wt%；
Xylitol, 0~16wt%；
Surplus is water.
Wherein, non-toxic inorganic sodium salt can be sodium citrate or NaCl or Na2HPO3.12H2O etc..
The temperature-sensitive hydrogel of adjustable response temperature proposed by the present invention contains the preparation method of cell material, specifically
Steps are as follows:
Take methylcellulose, polyethylene glycol-20000, non-toxic inorganic sodium salt, xylitol in 70~100 DEG C heat go from
Uniform stirring in sub- water, is uniformly dispersed, and is put into refrigerator cold-storage and stays overnight, is allowed to be completely dissolved, and adjustable response temperature can be obtained
The temperature-sensitive hydrogel of degree contains cell material.
Wherein, the concentration of methylcellulose used is 136.36mg/ml；The concentration of PEG-20000 used is 80mg/ml；
The concentration of non-toxic inorganic sodium salt used is 14.2mg/ml；The concentration of xylitol used is 0~200mg/ml.
The temperature-sensitive hydrogel of the adjustable response temperature of gained contains cell material, the weight percent of each component are as follows:
Methylcellulose, 12wt%；
PEG-20000,7.4wt%；
Non-toxic inorganic sodium salt, 1.4wt%；
Xylitol, 0~16wt%；
Surplus is water.
Further, the non-toxic inorganic sodium salt can be sodium citrate or NaCl or Na2HPO3.12H2O。
Further, the brand that the methylcellulose uses is Adamas, viscosity 15mPa.s, with the amount of 12wt%, system
Make hydrogel；The concentration of methylcellulose improves then too sticky, and methyl cellulose concentration reduces then its phase transition temperature
Also it reduces.It since the osmotic pressure of cell in vivo is 300mmol/L, therefore selects sodium dihydrogen phosphate as salt effect additive, adds
Entering amount is 14.2mg/ml, is cell maximum osmotic pressure value.Xylitol is added simultaneously to adjust the phase transition temperature of hydrogel, in fact
Now respond the adjustable of temperature.80mg/ml PEG-2000 is added to increase its gelation rate.
In the present invention, the adjusting of hydrogel phase transition temperature, such as xylose can be realized by adjusting Determination of Xylitol
When the mass percent of alcohol is 4% (concentration 40mg/ml), phase transition temperature is 34 DEG C, when xylitol mass percent
When for 8% (concentration 80mg/ml), phase transition temperature is 32 DEG C.
The temperature-sensitive hydrogel of adjustable response temperature provided by the invention contains cell material, contains cell infusion
Intracorporal method are as follows:
(1) the temperature-sensitive hydrogel solution and cell suspending liquid for the adjustable response temperature for obtaining the present invention are in low temperature
In being shaken on shaking table under environment, so that uniformly mixing, keeps being completely transformed into a gel state at 37 DEG C；
(2) gel state hydrogel-cell mixture is drawn with the syringe of removal syringe needle, is injected after loading onto syringe.
No. 1.2 syringe needle needle cylinder injections are used in the present invention.
Hydrogel provided by the invention is liquid at room temperature, is gel state when being higher than its phase transition temperature.It can be with
The phase transition temperature of gel is adjusted by the content of xylitol according to diseased region situation.Wherein, non-toxic inorganic sodium salt is due to thin
The effect of born of the same parents' osmotic pressure maintains ion concentration 300mmol/L, and the change of xylitol influences less Premeabilisation of cells pressure, therefore can
Change its phase transition temperature freely to adjust concentration so that material prepared by the present invention is more widely applied, PEG-2000 to
Increase its gelation rate, it is low to solve stem cell retention rate when being injected into internal, loses big problem.
Preparation method provided by the invention is simple cheap nontoxic, is suitble to industrialization, avoids the side effect of organic solvent, do
The safeguard protection for cell is arrived.The Injectable temperature sensitive gel of the prior art all uses external solution state, is injected into body
The technology condensed after interior, and after the present invention is mixed in vitro, solidified with cell using gel, it is injected in vivo, as wrapped up fruit
The jelly that can be inhaled method, yet there are no document report both at home and abroad at present.
Compared with the prior art, the advantages of the present invention are as follows: the present invention uses methylcellulose, various nontoxic by changing
The additive amount of additive effectively changes its phase transition temperature.Raw material sources are extensive, low in cost, and operating method is easy, technique
Simply, the prospect with industrial production application, can need to change the phase transition temperature of material according to the state of an illness, realize effective cell
Intelligence release.And biological nontoxic can carry cell.The hybrid material can realize hydrogel solution when temperature reduces, and release
Cell is put, provides a kind of thinking for treatment, is had in fields such as medicine controlled releasing, biological intelligence switch, biosensors extensive
Application.
Detailed description of the invention
Fig. 1 is to freeze after the 8% xylitol hydrogel solution that the embodiment of the present invention 1 provides is changed into gel state at 37 degree
Dry scanning electron microscope (SEM) photograph.
Fig. 2 is the heating rheogram (heating rate 0.3 for the 8% xylitol hydrogel solution that the embodiment of the present invention 1 provides
DEG C/min, strain 0.05% and frequency 1rad/s).
Fig. 3 is unenhanced, stress 0.1 of the 8% xylitol hydrogel solution that provides of the embodiment of the present invention 1 at 37 degree.
Fig. 4 is the 4% xylitol hydrogel MTT experiment data that the embodiment of the present invention 2 provides.
Fig. 5 is that 1 gel of embodiment provided in an embodiment of the present invention package dil staining cell shows fluorescent microscopy images (are presented solid
Determine state).
Fig. 6 is that 1 gel of embodiment provided in an embodiment of the present invention package dil staining cell discharges cell in pbs solution
(travelling state is presented) in shows fluorescent microscopy images.
Specific embodiment
The following examples are further illustrations of the invention, it is not intended to limit the scope of the invention.
Embodiment 1
Weigh 0.68182g methylcellulose, 0.4g PEG-20000 (80mg/ml), 0.179g Na2HPO3.12H2O
(14.2mg/ml), 0.4g xylitol (80mg/ml) is dissolved in 100 degree of deionized waters of 5ml, is put into 4 degree of ice after mixing evenly
Case is completely dissolved overnight.It tests rheology (0.3 DEG C/min of heating rate strains 0.05% and frequency 1rad/s) and obtains its gel temperature
Degree is at 31.8 degree.
Take wherein 1ml solution mixed with embryonic stem cell suspension, on shaking table after uniform stirring, be put into 37 degree of incubators
Form it into gel state within one hour.The hydrogel for becoming gel state is drawn with the syringe for removing syringe needle, injection lacks after installing syringe needle
Haemal tissue.
Embodiment 2
Weigh 0.68182g methylcellulose, 0.4g PEG-20000 (80mg/ml), 0.179g Na2HPO3.12H2O
(14.2mg/ml), 0.2g xylitol (40mg/ml) is dissolved in 100 degree of deionized waters of 5ml, is put into 4 degree of ice after mixing evenly
Case is completely dissolved overnight.It tests rheology (0.3 DEG C/min of heating rate strains 0.05% and frequency 1rad/s) and obtains its gel temperature
Degree is at 33.4 degree.
Take wherein 1ml solution mixed with embryonic stem cell suspension, on shaking table after uniform stirring, be put into 37 degree of incubators
Form it into gel state within one hour.The hydrogel for becoming gel state is drawn with the syringe for removing syringe needle, injection lacks after installing syringe needle
Haemal tissue.
The hole of comparative example 1:37 degree gel
1 gel of example is placed to holding 3 hours in 37 degree of water-baths, so that it goes completely into gel.It takes on a small quantity in liquid nitrogen
Middle temper is cold, is handled 24 hours with freeze dryer, removes moisture removal.Plane, which is opened, obtains section, observes under scanning electron microscope.
2 maxicell toxicity of comparative example；
MTT experiment method:
A. logarithmic phase cell is collected, concentration of cell suspension is adjusted, 100ul is added in every hole, and bed board makes cell tune density to be measured
To the hole 1000-10000, (edge hole is filled with sterile PBS).
B.5%CO2, 37 DEG C of incubations, until cell monolayer is paved with bottom hole (96 hole flat underside), the gel that concentration gradient is added soaks
Extract.
C.5%CO2, 37 DEG C incubation 16-48 hours, observe under inverted microscope.
D. 20ulMTT solution (5mg/ml, i.e. 0.5%MTT) is added in every hole, continues to cultivate 4h.
E. culture is terminated, culture solution in hole is carefully sucked.
F. 150ul dimethyl sulfoxide is added in every hole, sets low-speed oscillation 10min on shaking table, dissolves crystal sufficiently.In enzyme
Join the light absorption value in each hole of measurement at immune detector OD490nm.
G. it is arranged zeroing hole (culture medium, MTT, dimethyl sulfoxide) simultaneously, (cell, the drug of same concentrations are molten for control wells
Solve medium, culture solution, MTT, dimethyl sulfoxide)
Fig. 1 is to freeze after the 8% xylitol hydrogel solution that the embodiment of the present invention 1 provides is changed into gel state at 37 degree
Dry scanning electron microscope (SEM) photograph.As can be seen from the figure: its pore size can contain cell between 20-30 microns.
Fig. 2 is the heating rheogram (heating rate 0.3 for the 8% xylitol hydrogel solution that the embodiment of the present invention 1 provides
DEG C/min, strain 0.05% and frequency 1rad/s).As can be seen from the figure: its phase transition temperature is at 32 DEG C.
Fig. 3 is unenhanced, stress 0.1 of the 8% xylitol hydrogel solution that provides of the embodiment of the present invention 1 at 37 degree.From figure
In it can be seen that its mechanical strength is moderate, not only can protect cell, but also can be in injectable under curdled appearance.
Fig. 4 is the 8% xylitol hydrogel MTT experiment data that the embodiment of the present invention 2 provides.As can be seen from the figure: solidifying
Glue does not have bio-toxicity and even helps to cell growth.
Fig. 5 is 1 gel of embodiment provided in an embodiment of the present invention in 37 DEG C of package dil staining cell shows fluorescent microscopy images
(stationary state is presented).As can be seen from the figure: cell is contained in gel, is protected.
Fig. 6 is that 1 gel of embodiment provided in an embodiment of the present invention package dil staining cell discharges cell in pbs solution
(travelling state is presented) in shows fluorescent microscopy images.As can be seen from the figure: at low temperatures, cell is discharged from gel.
Foregoing description is only the description to present pre-ferred embodiments, is not any restriction to the scope of the invention.Appoint
Any change or modification what those skilled in the art makes according to the technology contents of the disclosure above should all regard
For equivalent effective embodiment, the range of technical solution of the present invention protection is belonged to.
Claims (9)
1. a kind of temperature-sensitive hydrogel of adjustable response temperature contains cell material, it is characterised in that: including following weight
The component of percentage:
Methylcellulose, 12wt%；
PEG-20000,7.4wt%；
Non-toxic inorganic sodium salt, 1.4wt%；
Xylitol, 0~16wt%；
Surplus is water.
2. the temperature-sensitive hydrogel of adjustable response temperature according to claim 1 contains cell material, feature exists
In: the non-toxic inorganic sodium salt is Na2HPO3·12H2O。
3. the preparation side that the temperature-sensitive hydrogel of adjustable response temperature according to claim 1 contains cell material
Method, which is characterized in that specific step is as follows:
Take methylcellulose, polyethylene glycol-20000, non-toxic inorganic sodium salt, xylitol in the deionized water of 70~100 DEG C of heat
Middle uniform stirring, is uniformly dispersed, and is put into refrigerator cold-storage and stays overnight, is allowed to be completely dissolved, and adjustable response temperature can be obtained
Temperature-sensitive hydrogel contains cell material.
4. the preparation side that the temperature-sensitive hydrogel of adjustable response temperature according to claim 3 contains cell material
Method, it is characterised in that: the concentration of the methylcellulose is 136.36mg/ml；The concentration of the PEG-20000 is 80mg/ml；
The non-toxic inorganic sodium salt is Na2HPO3·12H2O, concentration 14.2mg/ml；The concentration of the xylitol is 0~200mg/
ml。
5. the preparation side that the temperature-sensitive hydrogel of adjustable response temperature according to claim 3 contains cell material
Method, it is characterised in that: the viscosity of the methylcellulose is 15mPa.s.
6. the preparation side that the temperature-sensitive hydrogel of adjustable response temperature according to claim 3 contains cell material
Method, it is characterised in that: the phase transition temperature that the temperature-sensitive hydrogel of the adjustable response temperature contains cell material passes through
The mass percent for adjusting the xylitol is completed.
7. the preparation side that the temperature-sensitive hydrogel of adjustable response temperature according to claim 6 contains cell material
Method, it is characterised in that: when the mass percent of the xylitol is 4%, the Thermo-sensitive water of the adjustable response temperature
The phase transition temperature that gel contains cell material is 34 DEG C；
When the mass percent of the xylitol be 8% (concentration 80mg/ml) when, it is described it is adjustable response temperature it is temperature sensitive
Property hydrogel contain cell material phase transition temperature be 32 DEG C.
8. the temperature-sensitive hydrogel of adjustable response temperature according to claim 1 contains cell material, it is applied to packet
Carry the intracorporal method of cell infusion are as follows:
(1) by the temperature-sensitive hydrogel solution of the adjustable response temperature and cell suspending liquid at low ambient temperatures in shaking table
Upper concussion, so that uniformly mixing, keeps being completely transformed into a gel state at 37 DEG C；
(2) gel state hydrogel-cell mixture is drawn with the syringe of removal syringe needle, is injected after loading onto syringe.
9. the temperature-sensitive hydrogel of adjustable response temperature according to claim 8 contains cell material, it is applied to packet
It carries the intracorporal method of cell infusion: using No. 1.2 syringe needle needle cylinder injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810895373.8A CN109232995A (en) | 2018-08-08 | 2018-08-08 | The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810895373.8A CN109232995A (en) | 2018-08-08 | 2018-08-08 | The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109232995A true CN109232995A (en) | 2019-01-18 |
Family
ID=65070226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810895373.8A Pending CN109232995A (en) | 2018-08-08 | 2018-08-08 | The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109232995A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912850A (en) * | 2019-03-11 | 2019-06-21 | 同济大学 | Self-healing hydrogel encapsulating exosomes, preparation method and application thereof |
| CN113842493A (en) * | 2021-09-13 | 2021-12-28 | 深圳先进技术研究院 | Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel |
| CN114042188A (en) * | 2021-08-31 | 2022-02-15 | 上海市第六人民医院 | Composite hydrogel for promoting healing of aponeurosis and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102731791A (en) * | 2011-04-13 | 2012-10-17 | 北京大学 | Temperature-sensitive block copolymer and its hydrogel as well as application |
| WO2013011503A1 (en) * | 2011-07-20 | 2013-01-24 | Theracoat Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| CN103724976A (en) * | 2013-12-17 | 2014-04-16 | 苏潮宁 | Temperature-sensitive hydrogel and preparation method thereof |
-
2018
- 2018-08-08 CN CN201810895373.8A patent/CN109232995A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102731791A (en) * | 2011-04-13 | 2012-10-17 | 北京大学 | Temperature-sensitive block copolymer and its hydrogel as well as application |
| WO2013011503A1 (en) * | 2011-07-20 | 2013-01-24 | Theracoat Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| CN103724976A (en) * | 2013-12-17 | 2014-04-16 | 苏潮宁 | Temperature-sensitive hydrogel and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 林莹，等: "甲基纤维素温敏水凝胶的凝固及体外释药特性", 《清华大学学报》 * |
| 邝清林: ""温敏甲基纤维素基凝胶的转变及性质研究", 《中国优秀硕士论文全文数据库.工程科技Ⅰ辑》 * |
| 陈薇，等: "《生物技术发展年鉴.2013》", 31 December 2014, 军事医学科学出版社 * |
| 黄佩丽，等: "《基础元素化学》", 30 September 1994, 北京师范大学出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912850A (en) * | 2019-03-11 | 2019-06-21 | 同济大学 | Self-healing hydrogel encapsulating exosomes, preparation method and application thereof |
| CN109912850B (en) * | 2019-03-11 | 2021-03-02 | 同济大学 | Self-healing hydrogel encapsulating exosomes, preparation method and application thereof |
| CN114042188A (en) * | 2021-08-31 | 2022-02-15 | 上海市第六人民医院 | Composite hydrogel for promoting healing of aponeurosis and preparation method and application thereof |
| CN114042188B (en) * | 2021-08-31 | 2023-03-31 | 上海市第六人民医院 | Composite hydrogel for promoting healing of aponeurosis and preparation method and application thereof |
| CN113842493A (en) * | 2021-09-13 | 2021-12-28 | 深圳先进技术研究院 | Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel |
| CN113842493B (en) * | 2021-09-13 | 2022-12-02 | 深圳先进技术研究院 | Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Microneedle system for tissue engineering and regenerative medicine | |
| Kuang et al. | Injectable hydrogel with NIR light‐responsive, dual‐mode PTH release for osteoregeneration in osteoporosis | |
| Farsheed et al. | 3D printing of self‐assembling nanofibrous multidomain peptide hydrogels | |
| Liu et al. | Dual suppression effect of magnetic induction heating and microencapsulation on ice crystallization enables low-cryoprotectant vitrification of stem cell–alginate hydrogel constructs | |
| Qin et al. | Recent advances in ice templating: from biomimetic composites to cell culture scaffolds and tissue engineering | |
| Xu et al. | Injectable biodegradable hybrid hydrogels based on thiolated collagen and oligo (acryloyl carbonate)–poly (ethylene glycol)–oligo (acryloyl carbonate) copolymer for functional cardiac regeneration | |
| Klouda | Thermoresponsive hydrogels in biomedical applications: A seven-year update | |
| Li et al. | Injectable, highly flexible, and thermosensitive hydrogels capable of delivering superoxide dismutase | |
| Tong et al. | Recent progress in developing injectable matrices for enhancing cell delivery and tissue regeneration | |
| US20200253192A1 (en) | Zwitterionic microgels, their assemblies and related formulations, and methods for their use | |
| WO2020134385A1 (en) | Temperature-sensitive polymer, synthesis method thereof, and temperature-sensitive injectable hydrogel | |
| Park et al. | Dual-channel fluorescence imaging of hydrogel degradation and tissue regeneration in the brain | |
| Zheng et al. | Organoid‐loaded cryomicroneedles for biomimic hair regeneration | |
| Wu et al. | Preservation of small extracellular vesicle in gelatin methacryloyl hydrogel through reduced particles aggregation for therapeutic applications | |
| Fan et al. | Strong hydration ability of silk fibroin suppresses formation and recrystallization of ice crystals during cryopreservation | |
| WO2014005471A1 (en) | Thermosensitive injectable chitosan hydrogel product and use thereof | |
| CN109232995A (en) | The temperature-sensitive hydrogel of adjustable response temperature contains cell material and the preparation method and application thereof | |
| KR102102153B1 (en) | A bead for cell encapsulation and culture based on decellularized tissue, and use thereof | |
| Sun et al. | Thermosensitive chitosan hydrogel for implantable drug delivery: Blending PVA to mitigate body response and promote bioavailability | |
| Ishikawa et al. | On-demand retrieval of cells three-dimensionally seeded in injectable thioester-based hydrogels | |
| KR102192908B1 (en) | Method for manufacturing controlled releasable DDS device using thermosensitive hydrogel | |
| Zhang et al. | Thermoresponsive dendronized chitosan-based hydrogels as injectable stem cell carriers | |
| CN109627463A (en) | Hydrogel and pharmaceutical grade protein | |
| WO2023109801A1 (en) | Supramolecular hydrogel capable of lipophilic drug delivery, preparation method therefor, and use thereof | |
| Hu et al. | Microneedles with an anisotropic porous microstructure facilitate the transdermal delivery of small molecules, lipid nanoparticles, and T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |
|
| RJ01 | Rejection of invention patent application after publication |